
Dec 3 (Reuters) - Lockheed Martin said on Wednesday it has opened a hypersonics system integration lab at its Huntsville campus as it pushes to develop next-generation weapons.
Hypersonic weapons, which can travel at more than five times the speed of sound and evade traditional defenses, are at the centre of an arms race between the United States and China.
Lockheed's 17,000-square-foot facility will include advanced test equipment, simulation tools and an integration environment.
It is part of a larger capital program that now totals roughly $529 million and includes 719,000 square feet of facilities under construction or planned, the company said.
"Hypersonic weapons are reshaping the future of military defense by delivering unmatched speed and maneuverability that outpace traditional threats," said Holly Molmer, program management director for Lockheed Martin
In October, defense start-up Castelion said it won contracts to integrate its Blackbeard hypersonic strike weapon with current U.S. Army systems.
(Reporting by Aishwarya Jain in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
From Lounge chair to Money: Online Positions That Will Change Your Profession - 2
Find the Marvels of the World with These Travels - 3
Far-right leader Le Pen to attend Brigitte Bardot's funeral - 4
Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now. - 5
Shah Capital pushes for Novavax sale, warns of proxy fight
A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
Fundamental Home Machines: An Easy to understand Determination Guide
6 Solid Moving Administrations for a Calm Movement
Overlooked infertility care should be part of national health services, says WHO
Czech Republic's new premier: No money for Ukraine
Mojtaba Khamenei unconscious in Qom, not actually running Iran
Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
Israeli president concerned over proposed renaming of park
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths












